Glenmark Pharmaceuticals

Price chart

Previous close

₹2,594.90

Open

₹2,591.30

Day high

₹2,714.00

Day low

₹2,572.20

Listed on NSE since 7 February 2000.

Futures and options

Futures, 23 Nov expiry

₹2,689.00

Premium to the share price

+9.00 (+0.34%)

Futures open interest

27,281 contracts (+827 today)

Lot size (NOV 26)

375 shares

Source: NSE, 09-Nov-2026 12:04:08, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

3,043.50

R2

2,863.00

R1

2,726.50

CPR top

2,568.00

Pivot

2,546.00

CPR bottom

2,524.00

S1

2,409.50

S2

2,229.00

S3

2,092.50

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹73,096 Cr

P/E (trailing)

50.38

EPS (trailing)

₹51.41

Price to book

6.52

Dividend yield

0.19%

Return on equity

14.0%

Debt to equity

0.13

Profit margin

9.2%

Volume today

10.98 L

Average volume

6.49 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Glenmark Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Glenmark Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Glenmark Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Mumbai

Employees

16,946

Company website · Profile: Yahoo Finance

No headlines name Glenmark Pharmaceuticals in the last day or two.

• Dividend - Rs 2.50 Per Share

  Dividend · ex-date 31 August 2026

• Interim Dividend - Rs 2.50 Per Share

  Dividend · ex-date 3 October 2025

• Dividend - Rs 2.50 Per Share

  Dividend · ex-date 15 September 2025

• Dividend - Rs 2.50 Per Share

  Dividend · ex-date 13 September 2024

• Dividend - Rs 2.50 Per Share

  Dividend · ex-date 18 September 2023

• Annual General Meeting/Dividend - Rs 2.50 Per Share

  Dividend · ex-date 12 September 2022

• Annual General Meeting/Dividend - Rs 2.50 Per Share

  Dividend · ex-date 8 September 2021

• Annual General Meeting/Dividend - Rs 2.50 Per Share

  Dividend · ex-date 17 September 2020

Source: NSE. Latest first, 8 of 20.